Anti-Fibrinolytic Drugs - Mexico | Statista Market Forecast

Mexico's Anti-Fibrinolytic Drugs market is expected to reach a projected revenue of US$112.50m by 2024.
The market is also anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 4.51%, leading to a market volume of US$140.30m by 2029.
In terms of global comparison, United States is forecasted to generate the highest revenue, with an estimated amount of US$9.86bn in 2024.
"The demand for anti-fibrinolytic drugs in Mexico is steadily increasing, driven by a rising prevalence of cardiovascular diseases in the country."

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The demand for anti-fibrinolytic drugs in Mexico has been steadily increasing over the past few years.

Customer preferences: Mexican customers are increasingly seeking out anti-fibrinolytic drugs as a treatment option for a variety of medical conditions. The drugs are primarily used to prevent excessive bleeding during surgical procedures, but are also used to treat conditions such as heavy menstrual bleeding and nosebleeds.

Trends in the market: One of the key trends driving the growth of the anti-fibrinolytic drugs market in Mexico is the increasing number of surgical procedures being performed in the country. As the healthcare system in Mexico continues to improve, more people are gaining access to medical treatment, including surgical procedures. This has led to an increased demand for anti-fibrinolytic drugs to prevent excessive bleeding during these procedures. Another trend driving the growth of the market is the increasing prevalence of conditions that require treatment with anti-fibrinolytic drugs. For example, heavy menstrual bleeding is a common condition among women in Mexico, and anti-fibrinolytic drugs are often prescribed as a treatment option.

Local special circumstances: Mexico has a large and growing pharmaceutical industry, which has helped to drive the growth of the anti-fibrinolytic drugs market in the country. Many of the drugs used in Mexico are manufactured locally, which helps to keep prices down and ensures that there is a steady supply of drugs available.

Underlying macroeconomic factors: Mexico's economy has been growing steadily over the past few years, which has helped to increase access to healthcare and drive demand for medical treatments such as anti-fibrinolytic drugs. In addition, the country's population is growing and aging, which is also contributing to the increasing demand for healthcare services. Overall, the anti-fibrinolytic drugs market in Mexico is expected to continue growing in the coming years, driven by factors such as increasing access to healthcare, a growing population, and an increasing number of surgical procedures being performed in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.